

ColdZyme® sales continue to perform well

Q3

- Net sales reached SEK 12.3 (6.8) million.
- Loss after tax came in at SEK -6.5 (-10.1) million.
- Earnings per share were SEK -0.08 (-0.41).
- Cash and cash equivalents were SEK 49.9 (9.7) million.

Significant events in Q3

- Enzymatica completed a directed share issue, raising SEK 40 million before issue expenses.

Significant events after Q3

- Enzymatica signed exclusive agreements for Australia, New Zealand, Greece and Cyprus

First nine months

- Net sales increased to SEK 25.6 (16.9) million.
- Loss after tax came in at SEK -27.4 (-29.6) million.
- Earnings per share were SEK -0.49 (-1.19).

Financial ratios

(SEK million)	Q3 2016	Q3 2015	Jan–Sep 2016	Jan–Sep 2015	Full year 2015
Net sales	12.3	6.8	25.6	16.9	27.9
Gross margin, %	66	67	64	73	70
Operating profit/loss	-7.7	-9.9	-27.6	-29.4	-40.5
Cash flow from operating activities	-15.6	-12.7	-35.6	-25.5	-37.7
Average number of employees	22	17	20	15	16

(Zymetech is consolidated in Enzymatica's figures as at April 1, 2016)

CEO statement: Continued sales growth and new international agreements signed

The Company boasts year-on-year growth of 52% over the first nine months of the year, with total sales, including sales from Zymetech, coming in at SEK 25.6 million in comparison to SEK 16.9 million in the corresponding period of the previous year. Sales in Sweden continue to perform well and in September ColdZyme® reported a market share of around 7% in the cold segment in spite of a weak start to the cold season. Growth in September was 81%. Other established markets are exhibiting satisfactory growth, except for the UK, where efforts to find a suitable distributor are in progress. Sales have gotten off to a good start on the Finnish market which was recently established, while pre-launch work in Spain is proceeding according to plan, with the expected start of the cold season in November.

The Company pursued its financing strategy in Q3 by conducting a directed issue of 17.5 million shares to new long-term and financially strong owners. The funds raised for the Company by the issue creates financial stability for the Company's ongoing international expansion.

Our efforts to reel in excellent distribution partners remain our highest priority, and we signed a distribution agreement for Greece and Cyprus in October. This agreement was signed with Life NLB Ltd, a small company prepared to put in the financial resources

and commitment required to establish ColdZyme on these markets. Yesterday we signed a distribution agreement with Endeavour Consumer Health, Australia's largest distributor to pharmacies and the third largest in New Zealand. It is also our first contract in the southern hemisphere and a step towards a seasonal adjustment. We expect a launch in the 2018.

As previously announced, we expect to have the final results of our latest patient study ready by the end of the year. We are on track to meet higher government requirements in connection with the new EU legislation for medical devices on time. Adoption of the new legislation is expected early next year.

We enter the final chapter of 2016 with a boost from our sales growth and a rise in demand for our product on the Scandinavian market.


Fredrik Lindberg, CEO

Enzymatica at a glance

Enzymatica AB is a life science company whose business concept is to develop medical devices based on barrier technology and marine enzymes for self-care in major market segments. The Company developed ColdZyme®, a unique mouth spray for fighting colds, launched the product on seven markets and reached a position over the past winter as one of the most-sold cold products in Swedish pharmacies measured in SEK. Enzymatica has its own sales organization in Scandinavia and collaborates with a contract sales organization in the UK. Enzymatica also sells via distributors in Finland and Spain.

Our development focuses on medical devices for upper respiratory tract infections and oral health. An enzyme from deep-sea fish is a key sub-component in product development.

Enzymatica was founded in 2007, has its head office in Lund and has been listed on the Nasdaq First North since June 15, 2015.



ColdZyme is sold both in-house and via distributors and partners in Sweden, Denmark, Norway, Finland, the UK and Spain. An equivalent product under the PreCold brand is sold in Iceland by the acquired company Zymetech.

Q3 performance

ColdZyme boasts outstanding year-on-year Q3 sales growth on the Swedish market. ColdZyme (20 and 7 ml) best the total market in volume gained for sales to end consumers from Swedish pharmacies, gaining 17% in comparison to 4.5% for the total market, according to fresh statistics (Nielsen data).

In Denmark, Enzymatica's sales performed well year-on-year as well. However, this increase in sales cannot be seen in our billing yet because these sales were mainly from previous replenishment orders. In Finland, we are still in the introduction phase and therefore do not have any previous quarters to compare with yet. In Norway, Enzymatica is working on finding a distributor for the Norwegian market. Negotiations are in progress and we are waiting to make further marketing investments until this has been resolved. Sales of PreCold and skincare products in Iceland performed well in Q3.

In Spain, Esteve continued its ColdZyme prelaunch to pharmacies during the quarter. The market is expected to gain momentum in November when the cold season normally starts.

In the UK, efforts to find a powerful distributor for the market are continuing.

Sales, earnings and investments

Q3

Consolidated net sales for Q3 2016 came in at SEK 12.3



(6.8) million – an 81% year-on-year increase. The majority of the sales are from Swedish pharmacies. SEK 1.6 million of this increase in sales comes from Zymetech's business.

The gross margin for Q3 was 66% (67%). Enzymatica has experienced fluctuations in its gross margins between individual quarters as a result of the distribution of sales via its own organization or distributors, the product mix and exchange rates.

Total operating expenses for Q3 amounted to SEK 17.1 (15.4) million. This increase is mainly due to expenses related to the addition of Zymetech's R&D and production operations in Iceland and R&D expenses related to conducting the COLDPREV II clinical trial.

The consolidated operating loss was SEK -7.7 (-9.9) million.

Enzymatica capitalizes new development expenditure on an ongoing basis. Capitalized expenses for development projects for Q3 totaled SEK 1.3 (1.0) million.



First nine months

Consolidated net sales in the period from January to September 2016 came in at SEK 25.6 (16.9) million – a 52% year-on-year increase.

The gross margin for the period was 64% (73%).

Total operating expenses for the period were SEK 50.8 (44.3) million. This increase in total overhead costs is mainly due to expenses related to the addition of Zymetech's R&D and production operations in Iceland, R&D expenses related to conducting the COLDPREV II clinical trial and non-recurring expenses due to the acquisition of Zymetech.

The consolidated operating loss was SEK -27.6 (-29.4) million.

Enzymatica capitalizes new development expenditure on an

ongoing basis. Capitalized expenses for development projects during the period totaled SEK 6.8 (2.7) million.

Seasonal variations

Cold products have a seasonal peak in the winter, while sales level out in the summer months. Q3 2016 sales picked up in September.

Research and development

Strengthening the documentation for the ColdZyme® cold spray is a key part of Enzymatica's R&D activities.

Enzymatica's product development focuses both on in-depth studies aiming to better understand and broaden the use of ColdZyme® and on clinical trials in new areas. We expect to be able to present the results of the recently completed ColdPrev II study on new volunteer subjects at the end of the year.

The Company has been participating in a four-year research project on chronic oral cavity infections run by Malmö University with funding from Vinnova since the beginning of 2015. The objective is to add more medical devices to the company's range of products in the therapeutic areas of upper respiratory tract infections and oral health.

In addition, work is ongoing to certify the company to ISO standard 13485, a quality management system for medical devices.

Barrier technology with enzyme from deep-sea fish

An enzyme from a deep-sea fish is a key sub-component in Enzymatica's product development efforts for creating effective barriers against viruses and bacteria. The enzyme, which is called cold-adapted trypsin, is formed in the cod's pancreas and becomes hyperactive when it comes into contact with the warm skin and sinuses of humans. Together with glycerol, the enzyme forms a temporary barrier on the skin or sinuses. The barrier makes it more difficult for viruses and bacteria to locally infect cells and cause diseases.

Significant events in Q3

A directed share issue was completed in August, raising SEK 40 million for Enzymatica before issue expenses. Several new strategic investors have been brought on board in connection with the issue.

Funding

The Group's available funds at the end of the period totaled SEK 51.1 (9.7) million, of which SEK 49.9 (9.7) million were in cash and cash equivalents and SEK 1.2 (0) million in unutilized credit facilities. In addition to the above available funds, there are unutilized credit facilities with a maximum amount of SEK 9.8 million via factoring in the parent company. The proceeds of the new share issue in the amount of SEK 40 million before issue expenses were received by the Company in September 2016.

Cash flow from operating activities for the period totaled SEK -35.6 (-25.5) million. Cash flow from operating activities for Q3 came in at SEK -15.6 (-12.7) million.

Total cash flow for the period amounted to SEK 41.8 (-28.2) million.

Parent company

The parent company's sales for the period from January to September reached SEK 23.4 (16.9) million. Profit/loss before tax came in at SEK -21.5 (-29.6) million.

Parent company sales for Q3 came in at SEK 11.2 (6.8) million. Profit/loss before tax came in at SEK -5.1 (-10.1) million.

The parent company's investments in property, plant & equipment and intangible assets for the period totaled SEK 6.8 (2.8) million and cash flow was SEK 41.8 (-23.3) million.

Please see the consolidated figures for more information.

Staff

The number of people employed by the group, converted to full-time positions, was 22 (17) at the end of the period. 10 (8) of the employees were men and 12 (9) were women.

Significant events after the end of the period

In October, we signed a distribution agreement for Greece and Cyprus. This agreement was signed with Life NLB Ltd, a small company prepared to put in the financial resources and commitment required to establish ColdZyme on these markets. Yesterday we signed a distribution agreement with Endeavour Consumer Health, Australia's largest distributor to pharmacies and the third largest in New Zealand.

Acquisition of Zymetech ehf

On April 1, 2016, the group acquired 99.5 percent of the share capital in Zymetech ehf. in the form of a non-cash issue of 20,905,942 new shares and 3,982,084 new warrants in Enzymatica, giving the group a controlling interest in Zymetech ehf. The acquisition price is calculated on the basis of Enzymatica's closing price on the Nasdaq First North at March 31, 2016, which was the most recent date prior to completion of the transaction. The closing price was SEK 3.45 per share at that date. The warrants are valued at SEK 0.97 per warrant using the Black & Scholes option pricing model at March 31, 2016. The purchase price for all shares of Zymetech is thus SEK 76,343 thousand, given that non-controlling interests are measured at fair value.

This acquisition gives Enzymatica international exclusive rights to a patent-protected enzyme, a key component of ColdZyme® Mouth Spray, as well as control over production of the enzyme, access to international research and development expertise and Zymetech's research portfolio. After the acquisition, Enzymatica will thus have exclusive rights in countries with patent protection until 2020 and a technological lead of several years over the rest of the world. The goodwill arising as a result of the transaction is attributable to acquired client relationships (which are not separable) and synergy effects expected from the merger of the operations of the group and Zymetech ehf.

The identified surplus values of intangible assets total SEK 7,533 thousand, which are amortized over the respective useful lives of these assets. The decrease in identified surplus values of intangible assets in comparison to the preliminary acquisition analysis described in the previous quarterly report for the period from January to March is attributable to an adaptation to IFRS 3. This resulted in one internal client relationship no longer being included in intangible assets. According to IFRS, a final acquisition analysis is to be prepared on December 31, 2016. The consideration in the acquisition analysis is divided as follows:

All amounts in SEK thousand	
Purchase price	76 343
Book value of equity	-7 110
	69 233
Total value adjustments (net)	7 533
Deferred tax liability	-1 507
Goodwill	63 207
Minority shareholding	355

Zymetechns fair value of acquired net assets, goodwill and impact on the group's cash flow can be seen in the table below:

Actual value, All amounts in SEK thousands	
Intangible assets	13 641
Property, plant & equipment	2 656
Financial assets	1 568
Inventories	736
Trade receivables	411
Other receivables	2 211
Cash and cash equivalents	27
Deferred tax liability	-1 507
Current interest-bearing liabilities	-4 392
Trade payables	-320
Other liabilities	-1 896
Acquired assets (net)	13 137
Goodwill	63 207
Total purchase price	76 343
Non cash issue	-75 988
Minority shareholding	-355
Cash and cash equivalents, acquired subsidiary	-27
Transaction expenses	1 491
Issue expenses	3 644
Acquired subsidiary, effect upon consolidated cash flow	5 108

The receivables acquired are measured at fair value.

The fair value of the non-controlling interests in Zymetech ehf, which is an unlisted company, is calculated using the consideration for the acquisition of 0.5% of Zymetech ehf.

The total transaction costs came in at SEK 2,023 thousand. Issue-related expenses totaled SEK 3,644. SEK 1,491 thousand of the transaction costs impacted the 2016 loss (SEK 532 thousand 2015) for the group and were capitalized in the parent company. Issue expenses have been charged to equity.

For the period from April to September 2016, Zymetech ehf has contributed revenue of SEK 2,653 thousand and a loss of SEK -4,389 thousand to the consolidated income statement. The corresponding amounts contributed for the period from January to September 2016 were SEK 3,663 thousand in revenue and SEK -6,359 thousand in loss.

Other information

Group

Enzymatica AB (publ) (corporate identity no. 556719-9244), with its head office in Lund, Sweden, is the parent company of the following subsidiaries: Zymetech ehf (corporate identity no. 6406830589),

with its head office in Reykjavik, Iceland, Enzymatica Care AB (corporate identity no. 556701-7495), with its head office in Lund, Sweden, and Enzymatica North America Inc, (corporate identity no. 47-1030502), with its head office in Delaware, USA.

Accounting policies

This interim report has been prepared in compliance with IAS 34 Interim Financial Reporting. The consolidated financial statements have been prepared in compliance with the International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. The parent company's financial statements have been prepared in compliance with the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities. The recognition and measurement policies as well as the bases of estimates and judgements applied in the 2015 Annual Report have been applied in this interim report as well. New or revised IFRS standards that came into force in 2016 did not have any material impact on the group.

Segment reporting

Enzymatica's business currently only spans a single operating segment, Medical devices. Please see the income statement and balance sheet for reporting on this operating segment.

Information about risks and uncertainties

Enzymatica's business is exposed to several risks, both operational and financial risks. The operational risks mainly comprise uncertainty concerning product development, supplier agreements, product liability and distribution. For a more detailed description of the risks and uncertainties Enzymatica faces, please see the risk and sensitivity analysis in the 2015 Annual Report.

2017 AGM

Enzymatica's 2017 Annual General Meeting will be held in Lund on April 20, 2017.

Shareholders who wish to have an item added to the agenda of the AGM may submit a written request by email to:

ir@enzymatica.se or by regular mail to the following address:

Styrelsen, Enzymatica AB, Ideon Science Park, 223 70 Lund. Requests must be received no later than seven weeks prior to the AGM to be eligible for inclusion in the meeting notice and thus the AGM agenda.

Audit

This report was reviewed by the Company's auditors.

Upcoming financial information

Year-end report 2016	February 16, 2017
Interim report, Jan–March 2017	April 20, 2017
2017 AGM	April 20, 2017
Interim report, Jan–June 2017	July 20, 2017
Interim report, Jan–Sep 2017	November 1, 2017

The interim reports and annual report are available on Enzymatica's website www.enzymatica.se.

The Board of Directors and CEO hereby confirm that this interim report provides a true and fair view of the parent company's and group's business, financial position and results of operations, and describes material risks and uncertainties faced by the parent company and group companies.

Lund, November 3, 2016

Lennart Nilsson
Board Chair

Marianne Dicander Alexandersson
Board Member

Guðmundur Pálmason
Board Member

Sigurgeir Guðlaugsson
Board Member

Hans Pihl
Board Member

Nils Siegbahn
Board Member

Monica Wallter
Board Member

Fredrik Lindberg
CEO

For questions about this report, please contact:

Fredrik Lindberg, CEO, Enzymatica AB

Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com

Bengt Jöndell, Interim CFO, Enzymatica AB

Tel: +46 (0)703-77 71 70 | Email: bengt.jondell@enzymatica.com

Publication

Enzymatica AB (publ) is required by Swedish law (the Securities Market Act and/or the Financial Instruments Trading Act) to publish the information in this interim report. The information was submitted for publication on November 3, 2016 at 9:00 a.m.

Address

Enzymatica AB (publ)

Corporate identity no.: 556719-9244

Mailing address: Ideon Science Park, 223 70 LUND

Street address: Scheelevägen 19, Ideon, Lund

Tel: +46 (0)46-286 31 00 | info@enzymatica.se |

www.enzymatica.se

Enzymatica is listed on the Nasdaq First North. The Company is traded under the ticker symbol ENZY and ISIN code SE0003943620.

Enzymatica's certified advisor is Erik Penser Bankaktiebolag.

THIS IS A TRANSLATION FROM THE SWEDISH ORIGINAL

Review report

Enzymatica AB (publ), corporate identity number 556719-9244

To the Board of Directors of Enzymatica AB (publ)

Introduction

We have reviewed the condensed interim report for Enzymatica AB (publ) as at September 30, 2016 and for the nine months period then ended. The Board of Directors and the Managing Director are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of review

We conducted our review in accordance with the International Standard on Review Engagements, ISRE 2410 Review of Interim Financial Statements Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material aspects, in accordance with IAS 34 and the Swedish Annual Accounts Act regarding the Group, and in accordance with the Swedish Annual Accounts Act regarding the Parent Company.

Malmö, November 3, 2016

Ernst & Young AB

Göran Neckmar

Authorized Public Accountant

Consolidated Income Statement in Summary

All amounts in SEK thousand	Jul-Sep 2016	Jul-Sep 2015	Jan-Sep 2016	Jan-Sep 2015	Jan-Dec 2015
Operating income					
Net sales	12 340	6 813	25 644	16 860	27 912
Cost of goods sold	-4 212	-2 234	-9 291	-4 624	-8 486
Gross profit	8 128	4 579	16 353	12 236	19 426
Sales & Marketing expenses	-7 522	-6 714	-19 532	-20 710	-31 203
Administrative expenses	-5 548	-5 520	-18 014	-14 407	-20 906
Research and development costs	-4 048	-3 217	-13 720	-9 203	-10 898
Other operating income	13	9	466	9	9
Capitalized development expenditure	1 315	994	6 801	2 693	3 054
Operating profit/loss	-7 662	-9 869	-27 646	-29 382	-40 518
Profit/loss from financial items					
Interest income and similar profit/loss items	219	0	336	130	133
Interest expenses and similar profit/loss items	-163	-265	-1 204	-375	-445
Profit/loss after financial items	-7 606	-10 134	-28 515	-29 627	-40 830
Tax expenses	1 098	-	1 098	-	-
Profit/loss for the period	-6 508	-10 134	-27 417	-29 627	-40 830
Other comprehensive income:					
Total other comprehensive income, net of tax	0	0	0	0	0
Total comprehensive income for the period	-6 508	-10 134	-27 417	-29 627	-40 830
Share attributable to parent company shareholders	-6 508	-10 134	-27 417	-29 627	-40 830
Per share data	Jul-Sep 2016	Jul-Sep 2015	Jan-Sep 2016	Jan-Sep 2015	Jan-Dec 2015
Earnings per share, SEK (basic and diluted)	-0,08	-0,41	-0,49	-1,19	-1,64
Equity per share, SEK	1,75	1,33	1,75	1,33	0,88
Equity-asset ratio, %	87%	76%	87%	76%	50%
Number of outstanding shares	90 887 808	24 961 438	90 887 808	24 961 438	24 961 438
Average number of outstanding shares (basic and diluted)	79 221 141	24 961 438	56 132 304	24 961 438	24 961 438

Definitions of financial ratios

Earnings per share. Profit/loss for the period divided by average weighted number of shares

Equity-asset ratio. Equity divided by total assets.

Equity per share. Equity divided by number of shares at the end of the period.

Quarterly financial performance

All amounts in SEK thousand	Q3 2016	Q2 2016	Q1 2016	Q4 2015	Q3 2015
Net sales	12 340	4 892	8 412	11 052	6 813
Gross profit/loss	8 128	3 104	5 121	7 190	4 579
Gross margin in %	66%	63%	61%	65%	67%
Overhead costs	-17 118	-21 116	-13 032	-18 324	-15 442
Operating profit/loss	-7 662	-12 275	-7 709	-11 134	-9 869
Profit/loss for the period	-6 508	-12 809	-8 099	-11 203	-10 134
Cash flow	22 993	19 711	-866	-1 611	-13 762

Consolidated Balance Sheet in Summary

All amounts in SEK thousand	2016-09-30	2015-09-30	2016-06-30	2015-12-31
Assets				
Intangible assets	96 752	13 559	95 523	13 776
Property, plant & equipment	3 700	310	3 051	276
Financial assets	1 439	-	2 409	-
Inventories	8 695	13 014	10 837	11 410
Trade receivables	12 823	5 777	4 820	9 495
Other receivables	9 459	1 210	6 359	830
Cash and cash equivalents	49 903	9 676	26 910	8 065
Total assets	182 771	43 546	149 909	43 852
Equity and liabilities				
Equity	159 492	33 077	130 298	21 985
Kortfristiga skulder, ej räntebärande	6 183	-	-	-
Current interest-bearing liabilities	5 805	-	11 481	10 939
Trade payables	4 994	6 563	3 404	5 980
Other liabilities	6 297	3 906	4 726	4 948
Total equity and liabilities	182 771	43 546	149 909	43 852

Consolidated statement of changes in equity

All amounts in SEK thousand	2016-09-30	2015-09-30	2016-06-30	2015-12-31
Opening balance	21 985	62 425	21 985	62 425
New share issue	100 245	-	59 995	-
Issue expenses related to New share issue	-8 901	-	-5 132	-
Non cash issue in relation to acquisition of subsidiary	75 988	-	75 988	-
Issue expenses related to Non cash issue	-3 644	-	-2 842	-
Effect of employee share ownership plan	0	279	63	390
Minority shareholding	355	-	355	-
Exchange rate difference	881	-	794	-
Profit/loss for the period	-27 417	-29 627	-20 908	-40 830
Closing balance	159 492	33 077	130 298	21 985

Consolidated cash flow statement

All amounts in SEK thousand	Jul-Sep 2016	Jul-Sep 2015	Jan-Sep 2016	Jan-Sep 2015	Jan-Dec 2015
Profit/loss after financial items	-7 606	-10 134	-28 515	-29 627	-40 830
Adjustments for non-cash items	247	253	1 752	769	1 550
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capital	-7 359	-9 881	-26 763	-28 858	-39 280
Changes in working capital	-8 262	-2 836	-8 831	3 400	1 632
Cash flow from operating activities	-15 621	-12 717	-35 594	-25 458	-37 648
Acquisition of subsidiary	0	-	-5 108	-	-
Capitalization of development expenditure	-1 316	-994	-6 801	-2 693	-3 053
Acquisition/disposal of property, plant & equipment	-529	-51	-684	-93	-93
Cash flow from investing activities	-1 845	-1 045	-12 593	-2 786	-3 146
New share issue	40 250	-	100 245	-	-
Transaction costs attributable to new share issue	-299	-	-6 878	-	-
Change in bank overdraft facilities	507	-	-3 343	-	10 939
Cash flow from financing activities	40 458	0	90 024	0	10 939
Total cash flow for the period	22 993	-13 762	41 838	-28 244	-29 855
Cash and cash equivalents at start of period	26 910	23 438	8 065	37 920	37 920
Cash and cash equivalents at end of period	49 903	9 676	49 903	9 676	8 065

Parent company income statement

All amounts in SEK thousand	Jul-Sep 2016	Jul-Sep 2015	Jan-Sep 2016	Jan-Sep 2015	Jan-Dec 2015
Operating income					
Net sales	11 178	6 813	23 406	16 860	27 912
Cost of goods sold	-4 021	-2 234	-8 264	-4 624	-8 486
Gross profit	7 158	4 579	15 142	12 236	19 426
Sales & Marketing expenses	-7 032	-6 714	-18 697	-20 710	-31 203
Administrative expenses	-3 738	-5 519	-13 169	-14 406	-20 372
Research and development costs	-2 809	-3 217	-11 118	-9 203	-10 898
Other operating income	0	9	156	9	9
Capitalized development expenditure	1 315	994	6 801	2 693	3 054
Operating profit/loss	-5 106	-9 868	-20 885	-29 381	-39 984
Profit/loss from financial items					
Interest income and similar profit/loss items	308	1	308	113	117
Interest expenses and similar profit/loss items	-27	-261	-958	-375	-447
Profit/loss after financial items	-4 825	-10 128	-21 535	-29 643	-40 314
Tax expenses	-	-	-	-	-
Profit/loss for the period	-4 825	-10 128	-21 535	-29 643	-40 314

Parent company statement of comprehensive income

All amounts in SEK thousand	Jul-Sep 2016	Jul-Sep 2015	Jan-Sep 2016	Jan-Sep 2015	Jan-Dec 2015
Profit/loss for the period	-4 825	-10 128	-21 535	-29 643	-40 314
Other comprehensive income:	-	-	-	-	-
Total other comprehensive income, net of tax:	0	0	0	0	0
Total comprehensive income for the period	-4 825	-10 128	-21 535	-29 643	-40 314

Parent company balance sheet

All amounts in SEK thousand	2016-09-30	2015-09-30	2016-06-30	2015-12-31
Assets				
Intangible assets	20 109	13 558	18 937	13 776
Property, plant & equipment	178	310	211	276
Financial assets	78 135	111	78 135	111
Inventories	10 563	13 014	13 041	11 410
Trade receivables	8 266	5 777	4 308	9 495
Receivables from group companies	4 183	-	-	-
Other receivables	10 604	1 210	4 011	1 362
Cash and bank balances	49 818	9 600	26 559	7 988
Total assets	181 856	43 580	145 201	44 418
Equity and liabilities				
Equity	164 523	32 930	131 951	22 370
Long-term liabilities	6 183	-	-	-
Current interest-bearing liabilities	827	-	7 126	10 939
Liabilities to group companies	191	191	191	191
Trade payables	4 383	6 563	2 889	5 980
Other liabilities	5 749	3 896	3 043	4 938
Total equity and liabilities	181 856	43 580	145 201	44 418